Navigation Links
Dr. Paul Korner Promoted to Senior Vice President of Ferring International PharmaScience Center U.S.
Date:3/17/2009

PARSIPPANY, N.J., March 17 /PRNewswire/ -- Ferring Pharmaceuticals Inc., a specialty pharmaceutical company, announces the promotion of Paul Korner, M.D., M.B.A. to Senior Vice President of the Ferring International PharmaScience Center U.S. (FIPCUS), the drug development subsidiary for Ferring Pharmaceuticals Inc. Dr. Korner was formerly Vice President, Medical Affairs for Ferring's Infertility, Orthopaedics, Urology, and Gastroenterology therapeutic areas, as well as Product Safety. In his new role, Dr. Korner will be responsible for the clinical management of U.S. drug development.

"Dr. Korner has made tremendous strides in his first six months with Ferring, and is exceptionally well qualified to lead the clinical programs at our PharmaScience Center," said Wayne Anderson, President and CEO of Ferring Pharmaceuticals Inc., and Chairman of FIPCUS. "He will oversee the drug development of our rich pipeline of products as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas."

Dr. Korner joined Ferring in 2008 with a broad range of experience in medical affairs, clinical development, management and business development. During his first six months at Ferring, he restructured the Medical Affairs and Product Safety departments, created a Medical Information department, and was instrumental in the pre-launch activities for newly approved degarelix for injection.

Prior to joining the company, Dr. Korner was Vice President of Medical Affairs, Women's Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women's Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as Executive Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc., and Senior Director of Clinical Research and Development, Women's Health and Bone Repair for Wyeth Research.

Dr. Korner is a board certified obstetrician and gynecologist. He received his M.D. from Loyola University, Stritch School of Medicine near Chicago. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of urology, orthopaedic and infertility products in the U.S. market. They include: EUFLEXXA(R) (1% sodium hyaluronic acid), BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP), ENDOMETRIN(R) (progesterone) Vaginal Insert, ACTHREL(R) (corticorelin ovine triflutate for injection), PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), Degarelix for injection, and DESMOPRESSIN.

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For complete prescribing information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
2. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
3. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
6. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
7. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
8. Schering-Plough Announces Pricing of Senior Notes Offering
9. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
10. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
11. Solazyme Announces New Senior Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 /PRNewswire/ ... the formation of its Medical/Clinical Advisory Board.  This ... veterans who enhance the range and depth of ... of its novel prenatal diagnostic tests.  These experts ... strategic guidance for the company,s product development and ...
(Date:1/19/2017)... and GAITHERSBURG, Md. ... MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics ... of a definitive agreement for the merger of ... current investors include Novartis Venture Fund, HealthCap, Truffle ... be a fully-integrated and diversified immunotherapeutics company with ...
(Date:1/19/2017)... Staten Island, NY (PRWEB) , ... January 19, 2017 , ... ... expand at an exponential rate. The tremendous growth is accounted to two main ... to the table and the expanding network of vendors supplying FireflySci products all around ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
Breaking Biology News(10 mins):